[go: up one dir, main page]

LU91321I2 - Particule similaire au virus HPV18 (gardasil, silgard) - Google Patents

Particule similaire au virus HPV18 (gardasil, silgard)

Info

Publication number
LU91321I2
LU91321I2 LU91321C LU91321C LU91321I2 LU 91321 I2 LU91321 I2 LU 91321I2 LU 91321 C LU91321 C LU 91321C LU 91321 C LU91321 C LU 91321C LU 91321 I2 LU91321 I2 LU 91321I2
Authority
LU
Luxembourg
Prior art keywords
protein
contg
proteins
vlps
derived
Prior art date
Application number
LU91321C
Other languages
English (en)
Original Assignee
Csl Ltd
Univ Queensland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3775561&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91321(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Csl Ltd, Univ Queensland filed Critical Csl Ltd
Publication of LU91321I2 publication Critical patent/LU91321I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/20043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/802—Virus-based particle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
LU91321C 1991-07-19 2007-03-09 Particule similaire au virus HPV18 (gardasil, silgard) LU91321I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPK732291 1991-07-19

Publications (1)

Publication Number Publication Date
LU91321I2 true LU91321I2 (fr) 2007-05-09

Family

ID=3775561

Family Applications (8)

Application Number Title Priority Date Filing Date
LU91318C LU91318I2 (fr) 1991-07-19 2007-02-27 Particule similaire au virus HPV 16
LU91316C LU91316I2 (fr) 1991-07-19 2007-02-27 Particule similaire au virus HPV11
LU91317C LU91317I2 (fr) 1991-07-19 2007-02-27 Particule similaire au virus HPV6,HPV11,HPV16 et HPV18
LU91315C LU91315I2 (fr) 1991-07-19 2007-02-27 Particule similaire au virus HPV6
LU91321C LU91321I2 (fr) 1991-07-19 2007-03-09 Particule similaire au virus HPV18 (gardasil, silgard)
LU91386C LU91386I2 (fr) 1991-07-19 2007-12-14 CERVARIX - Particule similaire au virus HPV18
LU91387C LU91387I2 (fr) 1991-07-19 2007-12-14 CERVARIX - La combinaison des particules similaires au virus HPV16 et HPV18
LU91385C LU91385I2 (fr) 1991-07-19 2007-12-14 CERVARIX - Particule similaire au virus HPV16

Family Applications Before (4)

Application Number Title Priority Date Filing Date
LU91318C LU91318I2 (fr) 1991-07-19 2007-02-27 Particule similaire au virus HPV 16
LU91316C LU91316I2 (fr) 1991-07-19 2007-02-27 Particule similaire au virus HPV11
LU91317C LU91317I2 (fr) 1991-07-19 2007-02-27 Particule similaire au virus HPV6,HPV11,HPV16 et HPV18
LU91315C LU91315I2 (fr) 1991-07-19 2007-02-27 Particule similaire au virus HPV6

Family Applications After (3)

Application Number Title Priority Date Filing Date
LU91386C LU91386I2 (fr) 1991-07-19 2007-12-14 CERVARIX - Particule similaire au virus HPV18
LU91387C LU91387I2 (fr) 1991-07-19 2007-12-14 CERVARIX - La combinaison des particules similaires au virus HPV16 et HPV18
LU91385C LU91385I2 (fr) 1991-07-19 2007-12-14 CERVARIX - Particule similaire au virus HPV16

Country Status (16)

Country Link
US (5) US7476389B1 (fr)
EP (5) EP1207203A3 (fr)
JP (3) JP3828570B2 (fr)
KR (1) KR100240480B1 (fr)
AT (3) ATE332973T1 (fr)
AU (1) AU651727B2 (fr)
CA (1) CA2113712C (fr)
CY (5) CY2598B2 (fr)
DE (11) DE122007000085I1 (fr)
DK (3) DK0595935T3 (fr)
ES (3) ES2279020T3 (fr)
GE (1) GEP20084431B (fr)
LU (8) LU91318I2 (fr)
NL (8) NL300261I1 (fr)
SG (1) SG48769A1 (fr)
WO (1) WO1993002184A1 (fr)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2279020T3 (es) 1991-07-19 2007-08-16 The University Of Queensland Vacuna contra el papilomavirus humano.
PT647140E (pt) 1992-06-25 2007-12-27 Univ Georgetown Vacinas de papilomavírus
US20020164350A1 (en) 1992-09-03 2002-11-07 Lowy Douglas R. Chimeric papillomavirus-like particles
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
ATE494005T1 (de) * 1993-03-09 2011-01-15 Univ Rochester Herstellung von menschlichem papillomaviren hüllprotein und virus-ähnlichen teilchen
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
US8062642B1 (en) 1993-03-09 2011-11-22 University Of Rochester Production of papillomavirus capsid protein and virus-like particles
AU719837B2 (en) * 1993-03-31 2000-05-18 Cancer Research Campaign Technology Limited Pharmaceuticals based on papillomaviruses
GB9306731D0 (en) * 1993-03-31 1993-05-26 Cancer Res Campaign Tech Vaccines
GB2279651A (en) * 1993-07-01 1995-01-11 British Tech Group Synthetic peptides of human papillomavirus
GB9313556D0 (en) * 1993-07-01 1993-08-18 British Tech Group Synthetic peptides of human papillomavirus
AUPM358894A0 (en) * 1994-01-31 1994-02-24 Csl Limited Modified papilloma virus l2 protein and vlps formed therefrom
DE4415743C2 (de) * 1994-05-04 1996-10-10 Deutsches Krebsforsch Papillomviren, Mittel zu deren Nachweis sowie zur Therapie von durch sie verursachten Erkrankungen
US5888516A (en) * 1994-05-16 1999-03-30 Merck & Co. Inc. Recombinant papillomavirus vaccines
WO1995031532A1 (fr) * 1994-05-16 1995-11-23 Merck & Co., Inc. Vaccins contre le papillomavirus
AUPM566794A0 (en) * 1994-05-17 1994-06-09 University Of Queensland, The Process and product
IL113817A (en) * 1994-06-30 2001-03-19 Merck & Co Inc Polynucleotide vaccne for papillomavirus
AU717647B2 (en) * 1994-10-06 2000-03-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Chimeric papillomavirus-like particles
AU717932B2 (en) * 1994-10-06 2000-04-06 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Chimeric papillomavirus-like particles
DE4447664C2 (de) * 1994-10-07 1999-04-15 Lutz Prof Dr Gissmann Fusionsproteine, Verfahren zu deren Herstellung sowie deren Anwendung
DE59511047D1 (de) * 1994-10-07 2006-06-14 Univ Loyola Chicago Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung
AU2003235191B2 (en) * 1994-10-07 2006-09-21 Loyola University Of Chicago Papilloma virus-like particles, fusion proteins as well as processes for their production
DE19526752C2 (de) * 1995-07-21 1997-08-07 Lutz Prof Dr Gissmann Hocheffiziente Bildung von Papillomavirusähnlichen Partikeln
AR004464A1 (es) * 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
JP3958360B2 (ja) * 1995-02-24 2007-08-15 キャンタブ ファーマシューティカルズ リサーチ リミティド 免疫治療剤として役立つポリペプチド及びポリペプチド調製の方法
US5840306A (en) * 1995-03-22 1998-11-24 Merck & Co., Inc. DNA encoding human papillomavirus type 18
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
US5820870A (en) * 1995-03-22 1998-10-13 Merck & Co., Inc. Recombinant human papillomavirus type 18 vaccine
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
US5821087A (en) * 1995-03-30 1998-10-13 Merck & Co., Inc. Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
IL117591A0 (en) * 1995-03-30 1996-07-23 Merck & Co Inc Synthetic DNA encoding human papillomavirus type 11 L1 protein
SE9501512D0 (sv) * 1995-04-24 1995-04-24 Euro Diagnostica Ab Synthetic peptide-defined eptopes useful for vaccination against papillomavirus
CA2237224C (fr) * 1995-11-15 2006-06-27 Steven Ludmerer Particules synthetiques de type viral hpv11
US6908615B1 (en) 1996-03-18 2005-06-21 Merck & Co., Inc. DNA encoding human papilloma virus type 18
FR2749323B1 (fr) * 1996-06-04 1998-07-10 Pasteur Merieux Serums Vacc Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique
US7118754B1 (en) 1996-07-30 2006-10-10 Transgene S.A. Pharmaceutical composition for treating papillomavirus tumors and infection
FR2751879B1 (fr) * 1996-07-30 1998-10-30 Transgene Sa Composition pharmaceutique contre les tumeurs et infections a papillomavirus
ATE256734T1 (de) * 1996-10-04 2004-01-15 Merck & Co Inc Synthetische hpv16 virus-ähnliche partikel
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
WO1998025646A1 (fr) * 1996-12-09 1998-06-18 Merck & Co., Inc. Particules synthetiques de nature virale de type hpv16
DE69736779T2 (de) * 1996-12-20 2007-08-16 Merck & Co., Inc. Zusammensetzungen von rekombinanten papillomavirus vakzinen
JP2002508748A (ja) * 1997-05-01 2002-03-19 カイロン コーポレイション アジュバントとしてのウイルス様粒子の使用
JP2002510976A (ja) * 1997-07-03 2002-04-09 ユニバーシティ・オブ・コロラド・ユニバーシティ・テクノロジー・コーポレイション 均質のヒト・パピローマウイルスのカプソメアを含有する組成物、その製造方法、およびその診断的、予防的、治療的使用
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
US6962777B1 (en) * 1997-09-05 2005-11-08 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps), homogeneous vlp and capsomere compositions produced by said methods; use thereof as vehicle for improved purification, and delivery of active agents
US6228368B1 (en) 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
CA2229955C (fr) 1998-02-20 2003-12-09 Medigene Gmbh Formulations de vaccins contenant des capsomeres de papillomavirus; methodes d'utilisation
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
US6692752B1 (en) 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
AUPP765398A0 (en) 1998-12-11 1999-01-14 University Of Queensland, The Treatment of papillomavirus infections
DE19925235A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
DE19925199A1 (de) * 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
DE19925234A1 (de) * 1999-06-01 2000-12-14 Medigene Ag Capsomere, stabile Capsomere, Capside, VLPs, oder CVLPs bzw. damit beladenen Zellen und ihre Verwendung in Diagnostik und Therapie
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB0109297D0 (en) 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
AUPR446801A0 (en) 2001-04-18 2001-05-17 University Of Queensland, The Novel compositions and uses therefor
KR100785397B1 (ko) 2001-06-28 2007-12-13 아피메즈 주식회사 인체 파필로마 바이러스 유사 입자를 생산하는 재조합아데노바이러스 벡터 및 자궁경부암 생백신
DE10137102A1 (de) 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
EP1425423B1 (fr) 2001-08-13 2010-06-23 University of Rochester Immunisation transcutanee contre le papillomavirus avec un virus de type papillomavirus
US20050118139A1 (en) * 2001-08-23 2005-06-02 Lingyi Huang Vaccine using papilloma virus e proteins delivered by viral vector
KR20030067873A (ko) * 2002-02-08 2003-08-19 주식회사 유니크 솔레노이드 밸브
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
DE602004031681D1 (de) 2003-07-21 2011-04-14 Transgene Sa Multifunktionelle Cytokine
US7527948B2 (en) 2003-09-25 2009-05-05 Third Wave Technologies, Inc. Detection of HPV
DE602005022458D1 (de) 2004-09-10 2010-09-02 Asahi Glass Co Ltd Impfstoff gegen humanes papillomavirus zur oralen verabreichung
US8021992B2 (en) * 2005-09-01 2011-09-20 Taiwan Semiconductor Manufacturing Co., Ltd. High aspect ratio gap fill application using high density plasma chemical vapor deposition
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US8080643B2 (en) * 2006-09-05 2011-12-20 Third Wave Technologies, Inc. HPV primers
SI2484375T1 (en) 2006-09-26 2018-08-31 Infectious Disease Research Institute A vaccine composition comprising a synthetic adjuvant
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US8052968B2 (en) 2006-10-16 2011-11-08 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
EP2998316B1 (fr) 2007-03-02 2019-06-12 GlaxoSmithKline Biologicals S.A. Nouveau procédé et nouvelles compositions
RU2494106C2 (ru) * 2007-11-23 2013-09-27 Шанхай Зеран Биотекнолоджи Ко., Лтд. Гены, кодирующие главный капсидный белок l1 вируса папилломы человека, и их применение
CN101952436B (zh) 2008-01-09 2013-03-13 建国大学校产学协力团 基于杆状病毒的疫苗
US9623098B2 (en) 2008-05-26 2017-04-18 Cadila Healthcare Limited Combined measles-human papilloma vaccine
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
GB0820822D0 (en) 2008-11-13 2008-12-24 Inst Catala D Oncologia Novel product and processes
EP2414512A1 (fr) * 2009-04-03 2012-02-08 Deutsches Krebsforschungszentrum Augmentation de la production de particules analogues au papillomavirus avec un système d'expression de baculovirus modifié
HRP20161585T1 (hr) 2009-06-05 2016-12-30 Infectious Disease Research Institute Sintetski glukopiranozilni lipidi kao adjuvansi i cjepivni pripravci koji ih sadrže
JP5758385B2 (ja) 2009-06-19 2015-08-05 アイジェン インコーポレーテッド 子宮頸がんワクチン
WO2011026111A1 (fr) 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Distribution par voie orale d'un vaccin au gros intestin pour induire une immunité mucosale
EP2556377B1 (fr) 2010-04-08 2017-07-12 University of Pittsburgh - Of the Commonwealth System of Higher Education Analyse de cellules présentatrices d'antigène des lymphocytes b
CA2799205A1 (fr) 2010-05-25 2011-12-01 Qiagen Gaithersburg, Inc. Analyse de capture hybride a resultats rapides et sondes associees tronquees de maniere strategique
KR101349291B1 (ko) 2010-08-10 2014-01-10 한국생명공학연구원 고초균을 이용하여 자궁경부암 백신을 제조하는 방법
CA2832307A1 (fr) 2011-04-08 2012-10-18 Immune Design Corp. Compositions immunogenes et leurs procedes d'utilisation pour induire des reponses immunitaires humorales et cellulaires
EP2811981B1 (fr) 2012-02-07 2019-05-08 Infectious Disease Research Institute Formulations d'adjuvant amélioré comprenant des agonistes de tlr4 et leurs procédés d'utilisation
JP2015514696A (ja) 2012-03-18 2015-05-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ヒト・パピローマウイルスに対するワクチン接種方法
ES2673556T3 (es) 2012-05-16 2018-06-22 Immune Design Corp. Vacunas para el VHS-2
US9657076B2 (en) 2012-10-23 2017-05-23 Emory University GM-CSF and IL-4 conjugates, compositions, and methods related thereto
EP3711768A1 (fr) 2013-04-18 2020-09-23 Immune Design Corp. Monothérapie de gla destinée à être utilisée dans le traitement du cancer
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
JP6741580B2 (ja) 2013-12-31 2020-08-19 インフェクシャス ディズィーズ リサーチ インスティチュート 単一バイアルのワクチン製剤
WO2016149384A1 (fr) 2015-03-18 2016-09-22 University Of Massachusetts Compositions et vaccins à base de particules pseudovirales contre l'infection et la maladie provoquées par le virus d'epstein-barr
KR101908438B1 (ko) * 2016-02-05 2018-10-16 (주)피앤피바이오팜 Arsntd를 융합파트너로 이용한 수용성 및 활성형 재조합단백질의 생산방법 및 그 생산물
US10962534B2 (en) 2016-02-22 2021-03-30 Boehringer Ingelheim Vetmedica Gmbh Method for the immobilization of biomolecules
IL263030B2 (en) 2016-05-16 2024-11-01 Access To Advanced Health Inst Pegylated liposomes and methods of use
KR102392974B1 (ko) 2016-05-16 2022-05-02 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) Tlr 작용제를 함유하는 제제 및 사용 방법
RU2753874C2 (ru) 2016-06-01 2021-08-24 Инфекшес Дизис Рисёрч Инститьют Наноалюмочастицы, содержащие агент, регулирующий размер
ES3003260T3 (en) 2017-06-15 2025-03-10 Access To Advanced Health Inst Nanostructured lipid carriers and stable emulsions and uses thereof
CN111315406A (zh) 2017-09-08 2020-06-19 传染病研究所 包括皂苷的脂质体调配物及其使用方法
RU2681174C1 (ru) * 2018-07-12 2019-03-04 Закрытое акционерное общество научно-производственная компания "Комбиотех" Способ получения рекомбинантной вакцины для профилактики папилломавирусной инфекции человека, рекомбинантная вакцина
MX2021014363A (es) 2019-05-25 2022-02-21 Infectious Disease Res Inst Composicion y metodo para secar por pulverizacion una emulsion de vacuna adyuvante.
JP7017811B2 (ja) * 2020-02-13 2022-02-09 国立研究開発法人農業・食品産業技術総合研究機構 ウイルス様粒子及びその使用
AU2021337493A1 (en) 2020-09-04 2023-05-18 Access To Advanced Health Institute Co-lyophilized rna and nanostructured lipid carrier
JP2024506364A (ja) 2021-02-11 2024-02-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｈｐｖワクチンの製造
WO2023126589A1 (fr) * 2021-12-29 2023-07-06 Hitachi High-Tech Corporation Methode d'analyse d'images de microbes
WO2024052882A1 (fr) 2022-09-09 2024-03-14 Access To Advanced Health Institute Composition de vaccin immunogène incorporant une saponine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2524487B1 (fr) 1982-04-05 1985-11-22 Pasteur Institut Fragments d'adn codant pour des polypeptides contenant au moins un determinant antigenique des papillomavirus, notamment du type hpv 1a et polypeptides correspondants
US5071757A (en) 1986-10-06 1991-12-10 Kreider John W Methods for propagating fastidious human viruses and for producing purified suspensions thereof
US5045447A (en) 1989-03-15 1991-09-03 Minson Anthony C Method of producing antibodies to HPV
NL8902301A (nl) * 1989-09-14 1991-04-02 Rijksuniversiteit Humaan parvovirus b19 eiwitten, hun produktie en hun gebruik in diagnostische assays en vaccins.
WO1992016638A1 (fr) * 1991-03-14 1992-10-01 5 Prime --> 3 Prime, Inc. Vehicules de transduction pour le transfert de l'adn a une cellule de mammifere
ES2279020T3 (es) 1991-07-19 2007-08-16 The University Of Queensland Vacuna contra el papilomavirus humano.
PT647140E (pt) 1992-06-25 2007-12-27 Univ Georgetown Vacinas de papilomavírus
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
ATE494005T1 (de) 1993-03-09 2011-01-15 Univ Rochester Herstellung von menschlichem papillomaviren hüllprotein und virus-ähnlichen teilchen

Also Published As

Publication number Publication date
ES2279020T3 (es) 2007-08-16
HK1059271A1 (en) 2004-06-25
LU91318I2 (fr) 2007-04-27
DE69233687D1 (de) 2007-04-19
CA2113712A1 (fr) 1993-02-04
DE122007000017I1 (de) 2007-07-26
CA2113712C (fr) 2007-06-12
JP4255944B2 (ja) 2009-04-22
JPH07505042A (ja) 1995-06-08
GEP20084431B (en) 2008-07-25
DK1298211T3 (da) 2006-11-13
EP1298211A2 (fr) 2003-04-02
AU651727B2 (en) 1994-07-28
LU91316I2 (fr) 2007-04-27
DE69232967T2 (de) 2003-12-18
NL300262I1 (nl) 2007-05-01
LU91387I2 (fr) 2008-02-14
DE69232967D1 (de) 2003-04-24
US6613557B1 (en) 2003-09-02
ATE234925T1 (de) 2003-04-15
DE122007000085I1 (de) 2008-03-27
JP3828570B2 (ja) 2006-10-04
CY2007015I1 (el) 2009-11-04
EP1359156B1 (fr) 2007-03-07
LU91385I2 (fr) 2008-02-14
NL300314I1 (nl) 2008-02-01
NL300314I2 (nl) 2010-03-01
EP0595935A1 (fr) 1994-05-11
AU2366692A (en) 1993-02-23
CY2007030I1 (el) 2012-01-25
EP0595935B1 (fr) 2003-03-19
DE69233639T2 (de) 2007-05-31
DK1359156T3 (da) 2007-04-10
EP1471147A3 (fr) 2007-03-21
LU91317I2 (fr) 2007-04-27
NL300263I1 (nl) 2007-05-01
EP1359156A2 (fr) 2003-11-05
NL300266I1 (nl) 2007-05-01
US20040214331A1 (en) 2004-10-28
NL300312I1 (nl) 2008-02-01
KR100240480B1 (ko) 2000-03-02
LU91386I2 (fr) 2008-02-14
DE122007000086I1 (de) 2008-04-17
CY2007015I2 (el) 2016-08-31
CY2598B2 (en) 2010-03-03
ES2267890T3 (es) 2007-03-16
US7476389B1 (en) 2009-01-13
NL300260I1 (nl) 2007-05-01
SG48769A1 (en) 1998-05-18
JP2006115849A (ja) 2006-05-11
NL300261I1 (nl) 2007-05-01
ATE332973T1 (de) 2006-08-15
NL300313I1 (nl) 2008-02-01
ES2194839T3 (es) 2003-12-01
DK0595935T3 (da) 2003-07-21
LU91315I2 (fr) 2007-04-27
EP1207203A3 (fr) 2004-04-28
EP1359156A3 (fr) 2004-03-24
US7939082B2 (en) 2011-05-10
CY2007016I2 (el) 2009-11-04
US20070154902A1 (en) 2007-07-05
DE122007000023I1 (de) 2007-08-09
DE122007000084I1 (de) 2008-03-27
US20090252761A1 (en) 2009-10-08
CY2007034I1 (el) 2012-01-25
CY2007016I1 (el) 2009-11-04
JP2004000269A (ja) 2004-01-08
DE69233687T2 (de) 2007-10-18
EP1298211A3 (fr) 2003-04-16
DE122007000018I1 (de) 2007-05-24
ATE356142T1 (de) 2007-03-15
US7169585B2 (en) 2007-01-30
EP1207203A2 (fr) 2002-05-22
DE69233639D1 (de) 2006-08-24
DE122007000016I1 (de) 2007-05-24
EP0595935A4 (fr) 1995-03-29
CY2007030I2 (el) 2017-04-05
EP1298211B1 (fr) 2006-07-12
WO1993002184A1 (fr) 1993-02-04
EP1471147A2 (fr) 2004-10-27
DE122007000019I1 (de) 2007-07-26

Similar Documents

Publication Publication Date Title
LU91321I2 (fr) Particule similaire au virus HPV18 (gardasil, silgard)
NL300324I1 (nl) Op papillomavirus lijkende deeltjes, fusie-eiwitten alsook werkwijze
DE05075369T1 (de) Herstellung von menschlichem Papilloma-Virus-Capsid-Protein und virusähnlichen Teilchen
WO1999061052A3 (fr) Immunisation par voie orale au moyen de particules de type viral du papillomavirus
CA2339324A1 (fr) Systeme de distribution de proteine utilisant des particules humaines de type papillomavirus